Form 4: Kezar Life Sciences Director Acquires 50,000 Stock Options
SEC Form 4 Filing
Michael Kauffman, a director at Kezar Life Sciences, acquired 50,000 stock options on June 20, 2024, exercisable at $0.67 per share.
Summary
- Michael Kauffman, a director of Kezar Life Sciences, Inc. (KZR), filed a Form 4 on June 21, 2024, reporting a transaction.
- On June 20, 2024, Kauffman acquired 50,000 stock options with an exercise price of $0.67.
- These options vest on June 20, 2025, contingent upon continued service.
- Following the transaction, Kauffman directly owns 50,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This filing is a routine disclosure of insider transactions, providing transparency to investors regarding the actions of company directors. It's common for directors to receive stock options as part of their compensation.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of earliest transaction: Acquisition of 50,000 stock options. |
| 06/20/2025 | Vesting date for 100% of the stock options, contingent upon continued service. |
| 06/19/2034 | Expiration date of the stock options. |
| 06/21/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.